CYP2A13: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 48: | Line 48: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Cytochrome P450, family 2, subfamily A, polypeptide 13''', also known as '''CYP2A13''', is a human [[gene]].<ref name="entrez">{{cite web | title = Entrez Gene: CYP2A13 cytochrome P450, family 2, subfamily A, polypeptide 13| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=1553| accessdate = }}</ref> | '''Cytochrome P450, family 2, subfamily A, polypeptide 13''', also known as '''CYP2A13''', is a human [[gene]].<ref name="entrez">{{cite web | title = Entrez Gene: CYP2A13 cytochrome P450, family 2, subfamily A, polypeptide 13| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=1553| accessdate = }}</ref> | ||
| Line 82: | Line 82: | ||
{{refend}} | {{refend}} | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 23:18, 8 August 2012
| Cytochrome P450, family 2, subfamily A, polypeptide 13 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
 PDB rendering based on 1z10. | |||||||||||
| Identifiers | |||||||||||
| Symbols | CYP2A13 ; CYP2A; CPAD | ||||||||||
| External IDs | Template:OMIM5 Template:MGI HomoloGene: 85917 | ||||||||||
| |||||||||||
| RNA expression pattern | |||||||||||
 | |||||||||||
 | |||||||||||
 | |||||||||||
| More reference expression data | |||||||||||
| Orthologs | |||||||||||
| Template:GNF Ortholog box | |||||||||||
| Species | Human | Mouse | |||||||||
| Entrez | n/a | n/a | |||||||||
| Ensembl | n/a | n/a | |||||||||
| UniProt | n/a | n/a | |||||||||
| RefSeq (mRNA) | n/a | n/a | |||||||||
| RefSeq (protein) | n/a | n/a | |||||||||
| Location (UCSC) | n/a | n/a | |||||||||
| PubMed search | n/a | n/a | |||||||||
|
WikiDoc Resources for CYP2A13 |
|
Articles |
|---|
|
Most recent articles on CYP2A13 |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CYP2A13 at Clinical Trials.gov Clinical Trials on CYP2A13 at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CYP2A13
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating CYP2A13 Risk calculators and risk factors for CYP2A13
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CYP2A13 |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Cytochrome P450, family 2, subfamily A, polypeptide 13, also known as CYP2A13, is a human gene.[1]
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. Although its endogenous substrate has not been determined, it is known to metabolize 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a major nitrosamine specific to tobacco. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q.[1]
References
Further reading
- Fernandez-Salguero P, Gonzalez FJ (1995). "The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis". Pharmacogenetics. 5 Spec No: S123–8. PMID 7581481.
- Smith G, Stubbins MJ, Harries LW, Wolf CR (1999). "Molecular genetics of the human cytochrome P450 monooxygenase superfamily". Xenobiotica. 28 (12): 1129–65. PMID 9890157.
- Nelson DR, Zeldin DC, Hoffman SM; et al. (2004). "Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants". Pharmacogenetics. 14 (1): 1–18. PMID 15128046.
- Fernandez-Salguero P, Hoffman SM, Cholerton S; et al. (1995). "A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles". Am. J. Hum. Genet. 57 (3): 651–60. PMID 7668294.
- Hoffman SM, Fernandez-Salguero P, Gonzalez FJ, Mohrenweiser HW (1996). "Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19". J. Mol. Evol. 41 (6): 894–900. PMID 8587134.
- Koskela S, Hakkola J, Hukkanen J; et al. (1999). "Expression of CYP2A genes in human liver and extrahepatic tissues". Biochem. Pharmacol. 57 (12): 1407–13. PMID 10353262.
- Su T, Bao Z, Zhang QY; et al. (2000). "Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone". Cancer Res. 60 (18): 5074–9. PMID 11016631.
- Zhang X, Su T, Zhang QY; et al. (2002). "Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant". J. Pharmacol. Exp. Ther. 302 (2): 416–23. PMID 12130698.
- Saito S, Iida A, Sekine A; et al. (2003). "Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population". J. Hum. Genet. 48 (5): 249–70. doi:10.1007/s10038-003-0021-7. PMID 12721789.
- Wang H, Tan W, Hao B; et al. (2004). "Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK". Cancer Res. 63 (22): 8057–61. PMID 14633739.
- Cauffiez C, Lo-Guidice JM, Quaranta S; et al. (2004). "Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility". Biochem. Biophys. Res. Commun. 317 (2): 662–9. doi:10.1016/j.bbrc.2004.03.092. PMID 15063809.
- Cheng XY, Chen GL, Zhang WX; et al. (2004). "Arg257Cys polymorphism of CYP2A13 in a Chinese population". Clin. Chim. Acta. 343 (1–2): 213–6. doi:10.1016/j.cccn.2004.01.017. PMID 15115698.
- He XY, Shen J, Ding X; et al. (2005). "Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen". Drug Metab. Dispos. 32 (12): 1516–21. doi:10.1124/dmd.104.001370. PMID 15333516.
- Fujieda M, Yamazaki H, Kiyotani K; et al. (2005). "Eighteen novel polymorphisms of the CYP2A13 gene in Japanese". Drug Metab. Pharmacokinet. 18 (1): 86–90. PMID 15618722.
- Smith BD, Sanders JL, Porubsky PR; et al. (2007). "Structure of the human lung cytochrome P450 2A13". J. Biol. Chem. 282 (23): 17306–13. doi:10.1074/jbc.M702361200. PMID 17428784.